Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-522306-21-00
Authorised, not yet recruiting Phase II

Effectiveness of CITicoline (TRAUSAN) in preventing cognitive decline After DELirium in older adults with proximal hip fracture – The CITADEL randomized controlled trial

2025-522306-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Universita Degli Studi Di Milano Bicocca
Sponsor type
Educational Institution
Therapeutic area
Nervous System Diseases
Decision date
13/10/2025
Enrollment target
122
Sites
Italy

Condition studied

Cognitive profiles

Investigational medicinal product(s)

TRAUSAN 1000 mg soluzione orale

Eligibility

Age group
65+ years
Sex
Female, Male

Primary endpoint

The Montreal Cognitive Assessment (MoCA) performed before discharge and at 6 months post-randomization will allow to assess the primary objective.

Endpoint detail

Montreal Cognitive Assessment (MoCA) performed before discharge and at 3 and 6months post-randomization, Short Physical Performance Battery (SPPB), performed at 3 and 6months post-randomization, Rates of adverse events (quantity/seriousness) during the 6-months follow-up after randomization

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522306-21-00 on CTIS ↗ ← All trials in the EU